Paratek Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Paratek Pharmaceuticals generated cash of -$66,141,000, which is less than the previous year. Cash used in financing activities reached the amount of $5,093,000 last year. Net change in cash is therefore -$46,244,000.
Cash Flow
| 2013 | -14.81M | -15.06M | 445K |
|---|---|---|---|
| 2014 | -18.53M | 13.66M | 99.51M |
| 2015 | -54.68M | -603K | 90.73M |
| 2016 | -94.09M | -74.75M | 90.51M |
| 2017 | -78.57M | -42.00M | 103.03M |
| 2018 | -81.17M | -127.87M | 220.72M |
| 2019 | -134.04M | 134.55M | 57.62M |
| 2020 | -103.42M | 92.49M | 11.34M |
| 2021 | -48.27M | 4.51M | 18.33M |
| 2022 | -66.14M | 14.80M | 5.09M |
PRTK Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 80.61M | 106.04M | 105.63M | 47.50M | 35.82M | 52.96M | 131.30M | 95.85M | 1.21M | 39.36M |
Operating activities | ||||||||||
Net income | -63.56M | -59.08M | -96.54M | -128.79M | -112.35M | -89.06M | -111.63M | -70.86M | -17.83M | -27.44M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 490K | 391K | 578K | -1.29M | -1.06M | 1.26M | 2.30M | 714K | 196K | 90K |
Stock-based compensation expense | 12.31M | 14.33M | 10.24M | 14.29M | 25.49M | 16.90M | 10.79M | 5.06M | 706K | 3.33M |
| Deferred income tax benefit | 12.31M | 14.33M | 10.24M | 14.29M | 25.49M | 16.90M | 10.79M | 5.06M | 706K | 3.33M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -40.42M | -21.78M | -7.45M | -11.22M | 4.44M | -4.83M | 4.96M | -2.70M | -4.76M | 0 |
Inventories | -9.09M | -15.50M | -11.76M | -10.85M | -715K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 7.67M | 6.76M | 1.57M | -623K | -641K | -4.22M | 2.06M | 14.02M | -6.40M | -588K |
Cash generated by operating activities | -66.14M | -48.27M | -103.42M | -134.04M | -81.17M | -78.57M | -94.09M | -54.68M | -18.53M | -14.81M |
Investing activities | ||||||||||
Purchases Of Investments | -15.16M | -15.11M | -29.62M | -102.20M | -292.86M | -180.28M | -135.79M | 0 | 0 | -69.81M |
Investments In Property Plant And Equipment | -36K | -373K | -376K | -239K | -60K | -1.11M | -690K | -856K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | -239K | -715K | 0 | 0 | 0 | 13.68M | 0 |
Cash generated by investing activities | 14.80M | 4.51M | 92.49M | 134.55M | -127.87M | -42.00M | -74.75M | -603K | 13.66M | -15.06M |
Financing activities | ||||||||||
Common Stock Issued | 7.32M | 18.39M | 21.89M | 26.55M | 51.51M | 82.79M | 70.93M | 71.27M | 89.76M | 445K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -319K | -70M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 5.09M | 18.33M | 11.34M | 57.62M | 220.72M | 103.03M | 90.51M | 90.73M | 99.51M | 445K |
Net Change In Cash | -46.24M | -25.43M | 415K | 58.13M | 11.67M | -17.54M | -78.34M | 35.44M | 94.64M | -29.43M |
Cash at end of period | 34.37M | 80.61M | 106.04M | 105.63M | 47.50M | 35.41M | 52.96M | 131.30M | 95.85M | 9.93M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |